-
Je něco špatně v tomto záznamu ?
Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study
R. von Moos, JJ. Body, O. Guenther, E. Terpos, YP. Acklin, J. Finek, J. Pereira, N. Maniadakis, G. Hechmati, S. Talbot, H. Sleeboom,
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2012
Free Medical Journals
od 2012-06-01
PubMed Central
od 2012
Europe PubMed Central
od 2012 do 2020
Open Access Digital Library
od 2012-06-01
Open Access Digital Library
od 2012-01-01
Open Access Digital Library
od 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2012
- Publikační typ
- časopisecké články MeSH
Background: Bone metastases and lytic lesions due to multiple myeloma are common in advanced cancer and can lead to debilitating complications (skeletal-related events [SREs]), including requirement for radiation to bone. Despite the high frequency of radiation to bone in patients with metastatic bone disease, our knowledge of associated healthcare resource utilization (HRU) is limited. Methods: This retrospective study estimated HRU following radiation to bone in Austria, the Czech Republic, Finland, Greece, Poland, Portugal, Sweden and Switzerland. Eligible patients were ≥ 20 years old, had bone metastases secondary to breast, lung or prostate cancer, or bone lesions associated with multiple myeloma, and had received radiation to bone between 1 July 2004 and 1 July 2009. HRU data were extracted from hospital patient charts from 3.5 months before the index SRE (radiation to bone preceded by a SRE-free period of ≥ 6.5 months) until 3 months after the last SRE that the patient experienced during the study period. Results: In total, 482 patients were included. The number of inpatient stays increased from baseline by a mean of 0.52 (standard deviation [SD] 1.17) stays per radiation to bone event and the duration of stays increased by a mean of 7.8 (SD 14.8) days. Outpatient visits increased by a mean of 4.24 (SD 6.57) visits and procedures by a mean of 8.51 (SD 7.46) procedures. Conclusion: HRU increased following radiation to bone across all countries studied. Agents that prevent severe pain and delay the need for radiation have the potential to reduce the burden imposed on healthcare resources and patients.
Biostatistics Amgen Ltd Uxbridge UK
Centre for Observational Research Amgen Ltd Uxbridge UK
Centre Hospitalier Universitaire Brugmann Université Libre de Bruxelles Brussels Belgium
Department of Health Services Management National School of Public Health Athens Greece
HAGA Hospital The Hague Netherlands
Health Economics Amgen GmbH Zug Switzerland
Kantonsspital Graubünden Chur Switzerland
University Hospital Plzeň Czech Republic
University of Athens School of Medicine Alexandra University Hospital Athens Greece
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18009904
- 003
- CZ-PrNML
- 005
- 20210204121925.0
- 007
- ta
- 008
- 180404s2018 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jbo.2018.01.003 $2 doi
- 035 __
- $a (PubMed)29577024
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a von Moos, Roger $u Kantonsspital Graubünden, Chur, Switzerland.
- 245 10
- $a Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study / $c R. von Moos, JJ. Body, O. Guenther, E. Terpos, YP. Acklin, J. Finek, J. Pereira, N. Maniadakis, G. Hechmati, S. Talbot, H. Sleeboom,
- 520 9_
- $a Background: Bone metastases and lytic lesions due to multiple myeloma are common in advanced cancer and can lead to debilitating complications (skeletal-related events [SREs]), including requirement for radiation to bone. Despite the high frequency of radiation to bone in patients with metastatic bone disease, our knowledge of associated healthcare resource utilization (HRU) is limited. Methods: This retrospective study estimated HRU following radiation to bone in Austria, the Czech Republic, Finland, Greece, Poland, Portugal, Sweden and Switzerland. Eligible patients were ≥ 20 years old, had bone metastases secondary to breast, lung or prostate cancer, or bone lesions associated with multiple myeloma, and had received radiation to bone between 1 July 2004 and 1 July 2009. HRU data were extracted from hospital patient charts from 3.5 months before the index SRE (radiation to bone preceded by a SRE-free period of ≥ 6.5 months) until 3 months after the last SRE that the patient experienced during the study period. Results: In total, 482 patients were included. The number of inpatient stays increased from baseline by a mean of 0.52 (standard deviation [SD] 1.17) stays per radiation to bone event and the duration of stays increased by a mean of 7.8 (SD 14.8) days. Outpatient visits increased by a mean of 4.24 (SD 6.57) visits and procedures by a mean of 8.51 (SD 7.46) procedures. Conclusion: HRU increased following radiation to bone across all countries studied. Agents that prevent severe pain and delay the need for radiation have the potential to reduce the burden imposed on healthcare resources and patients.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Body, Jean-Jacques $u Centre Hospitalier Universitaire Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
- 700 1_
- $a Guenther, Oliver $u Centre for Observational Research, Amgen Ltd, Uxbridge, UK.
- 700 1_
- $a Terpos, Evangelos $u University of Athens School of Medicine, Alexandra University Hospital, Athens, Greece.
- 700 1_
- $a Acklin, Yves Pascal $u Kantonsspital Graubünden, Chur, Switzerland.
- 700 1_
- $a Finek, Jindrich $u University Hospital, Plzeň, Czech Republic.
- 700 1_
- $a Pereira, João $u Universidade Nova de Lisboa, National School of Public Health, Public Health Research Centre (CISP), Lisbon, Portugal.
- 700 1_
- $a Maniadakis, Nikos $u Department of Health Services Management, National School of Public Health, Athens, Greece.
- 700 1_
- $a Hechmati, Guy $u Health Economics, Amgen (Europe) GmbH, Zug, Switzerland.
- 700 1_
- $a Talbot, Susan $u Biostatistics, Amgen Ltd, Uxbridge, UK.
- 700 1_
- $a Sleeboom, Harm $u HAGA Hospital, The Hague, Netherlands.
- 773 0_
- $w MED00190568 $t Journal of bone oncology $x 2212-1366 $g Roč. 10, č. - (2018), s. 49-56
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29577024 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20210204121922 $b ABA008
- 999 __
- $a ind $b bmc $g 1287389 $s 1006716
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 10 $c - $d 49-56 $e 20180205 $i 2212-1366 $m Journal of bone oncology $n J Bone Oncol $x MED00190568
- LZP __
- $a Pubmed-20180404